Table 2.
Clinicopathological characteristics of four patients with EC involving ECP.
| Case No | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| Age | 33 years | 57 years | 57 years | 52 years |
| Imaging finding | 8.6-cm solid and cystic bilateral ovarian masses; borderline-sized pelvic and retroperitoneal lymph nodes; peritoneal carcinomatosis |
8.6-cm solid and cystic left ovarian mass; 3.4-cm EM mass; enlarged retroperitoneal lymph nodes; peritoneal carcinomatosis |
1-cm EM mass; no lymph node enlargement; no peritoneal seeding |
No identifiable EM lesion; no lymph node enlargement; no peritoneal seeding |
| Clinical impression | Ovarian cancer | Concurrent ovarian and EM cancers | EM cancer | MRI-invisible EM cancer |
| Neoadjuvant chemotherapy | Paclitaxel-carboplatin (three cycles) | Not received | Not received | Not received |
| Surgical procedure | TH, BSO, PLND, PALND, low anterior resection, omentectomy | TH, BSO, PLND, small bowel resection, appendectomy, omentectomy, peritonectomy | TH, BSO, PLND | TH, BSO |
| Final pathological diagnosis | Stage IIIC grade 3 EC (ovary) | Stage IIIC grade 3 EC (ovary); stage IB grade 1 EC (EM) |
Stage IA grade 1 EC (EM) | Stage IA grade 1 EC (EM) |
| Greatest dimension of ECP | 17 mm | 19 mm | 11 mm | 16 mm |
| Greatest dimension of EC | 6 mm | 3 mm | 4 mm | 10 mm |
| Invasion depth into polyp stroma | 1 mm | 0.3 mm | 0.3 mm | 1 mm |
| Polypectomy resection margin involvement (safety distance) | NA | NA | Absent (5 mm) | Absent (<1 mm) |
| Post-operative treatment | Paclitaxel-carboplatin (three cycles) | Paclitaxel-carboplatin (three cycles) | Not received | Not received |
| Post-operative recurrence | Bone (sternum and rib) | Mesentery | Absent | Absent |
| Disease-free survival | 49 months | 3 months | 24 months | 15 months |
| Treatment for recurrence | Complete surgical excision | Pembrolizumab (regimen change) | Not received | Not received |
| Survival status | Alive | Alive | Alive | Alive |
| Overall survival | 67 months | 3 months | 24 months | 15 months |
BSO: Bilateral salpingo-oophorectomy; EM: endometrium; MRI: magnetic resonance imaging; PALND: para-aortic lymph node dissection; PLND: pelvic lymph node dissection; TH: total hysterectomy.